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ABSTRACT.
Purpose: Extracellular matrix metalloproteinase inducer (EMMPRIN) pro-
motes angiogenesis through matrix metalloproteinases (MMPs) and vascular
endothelial growth factor (VEGF) production. We investigated the expression
levels of EMMPRIN and correlated these levels with VEGF, MMP-1 and
MMP-9 in proliferative diabetic retinopathy (PDR). In addition, we examined
the expression of EMMPRIN in the retinas of diabetic rats and the eﬀect of
EMMPRIN on the induction of angiogenesis regulatory factors in human retinal
microvascular endothelial cells (HRMECs).
Methods: Vitreous samples from 40 PDR and 19 non-diabetic patients,
epiretinal membranes from 12 patients with PDR, retinas of rats and
HRMECs were studied by enzyme-linked immunosorbent assay (ELISA),
immunohistochemistry, Western blot analysis, zymography analysis and
RT-PCR.
Results: We showed a signiﬁcant increase in the expression of EMMPRIN,
VEGF, MMP-1 and MMP-9 in vitreous samples from PDR patients
compared with non-diabetic controls (p < 0.0001; p = 0.001; p = 0.009;
p < 0.0001, respectively). Signiﬁcant positive correlations were found between
the levels of EMMPRIN and the levels of VEGF (r = 0.38; p = 0.003),
MMP-1 (r = 0.36; p = 0.005) and MMP-9 (r = 0.46; p = 0.003). In
epiretinal membranes, EMMPRIN was expressed in vascular endothe-
lial cells and stromal cells. Signiﬁcant increase of EMMPRIN mRNA
was detected in rat retinas after induction of diabetes. EMMPRIN
induced hypoxia-inducible factor-1a, VEGF and MMP-1 expression in
HRMEC.
Conclusions: These results suggest that EMMPRIN/MMPs/VEGF pathway is
involved in PDR angiogenesis.
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Introduction
Ischaemia-induced angiogenesis, a pro-
cess by which new blood vessels are
formed from pre-existing ones, is the
pathological hallmark feature in the
ocular microenvironment of patients
with proliferative diabetic retinopathy
(PDR). This process takes place as a
consequence of an angiogenic switch,
which allows the sprouting of blood
vessels within tissues (Hanahan &
Folkman 1996; Carmeliet 2003).
Angiogenesis is a multistep process
requiring the degradation of the base-
ment membrane and the extracellular
matrix (ECM), endothelial cell migra-
tion, endothelial cell proliferation and
capillary tube formation (Deryugina &
Quigley 2010). To form new blood
vessels, activated endothelial cells must
degrade the basement membrane of the
original vessel and remodel the ECM
around neovascular sites (Deryugina &
Quigley 2010). Proteases, such as
matrix metalloproteinases (MMPs),
have been implicated in this process
(Deryugina & Quigley 2010). In the
ocular microenvironment of patients
with PDR, the levels of the MMPs
MMP-1, MMP-7 and MMP-9 are
increased dramatically (Abu El-Asrar
et al. 2013). This upregulation of
MMPs is linked to angiogenesis and
progression of PDR. In addition to
removing the physical barrier to new
vessel growth, MMPs may facilitate
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pathologic neovascularization through
stimulation of the production of vas-
cular endothelial growth factor
(VEGF) (Hollborn et al. 2007) and
the proteolytic release of VEGF from
the ECM-associated reservoirs (Hawin-
kels et al. 2008; Ebrahem et al. 2010),
resulting in increased VEGF bioavail-
ability and triggering the VEGF-driven
angiogenic switch.
Among the angiogenic regulators,
VEGF is known to be a major factor in
PDR that promotes neovascularization
and vascular leakage (Spranger &
Pfeiﬀer 2001). Vascular endothelial
growth factor (VEGF) exerts its angio-
genic eﬀects by binding to its main
receptor VEGFR-2 (KDR) (Shibuya
2006). Hypoxia-inducible factor-1a
(HIF-1a) is a transcription factor that
accumulates in cells during hypoxia
and it heterodimerizes with the consti-
tutively expressed HIF-1b subunit,
triggering the activation of many genes
encoding proteins that regulate angio-
genesis, such as VEGF (Huang et al.
1998; Yamakawa et al. 2003; Sayed
& Mahmoud 2016). Hypoxia-inducible
factor-1a (HIF-1a) may be a target
for inﬂammatory events in diabetic
retinopathy (Gao et al. 2016). Angio-
genesis depends onmultiple factors, and
when the activity of one angiogenic
factor such as VEGF is suppressed, the
expression of other angiogenic factors
may appear (Dorrell et al. 2007). Ther-
apeutic regulation of angiogenesis has
emerged as an attractive approach for
the treatment of PDR (Salam et al.
2011). To aid the progress of these
strategies, amore comprehensive under-
standing of the molecules that regulate
angiogenesis in PDR is of value to
identify additional therapeutic targets.
Extracellular matrix metallopro-
teinase inducer (EMMPRIN), also
known as basigin and cluster of diﬀer-
entiation (CD) 147, is a highly glyco-
sylated member of the immunoglobulin
superfamily. Increased EMMPRIN
expression in cancer tissue is associated
with increased synthesis of several
MMPs and VEGF, increased angio-
genesis, clinically aggressive behaviour
and poor prognosis (Van den Oord
et al. 1997; Tang et al. 2005; Yan et al.
2005; Weidle et al. 2010). Therefore,
EMMPRIN probably functions as an
upstream modulator of MMPs and
VEGF production in the tumour local
environment. In the context of inﬂam-
matory diseases, EMMPRIN is
relatively understudied (Agrawal &
Yong 2011), although it has been
suggested as a target for intervention
with neutralizing antibodies in animal
models of asthma-mediated lung
inﬂammation (Gwinn et al. 2006) and
experimental autoimmune encephalitis
as a model of multiple sclerosis (Agra-
wal et al. 2012). Within the eye,
EMMPRIN expression has been
detected in the corneal and conjuncti-
val epithelium, the endothelium, and in
the stromal keratocytes, the retinal
pigment epithelium, several retinal lay-
ers and nerve ﬁbres in the optic nerve
head. In addition, solubilized EMM-
PRIN was detected in aqueous humour
and vitreous samples and in tear ﬂuids
(M€a€att€a et al. 2006).
Given the key roles of EMMPRIN
in angiogenesis, we hypothesized that
EMMPRIN may be involved in the
pathogenesis of PDR. To test this
hypothesis, we investigated the expres-
sion of EMMPRIN in the vitreous
ﬂuid and epiretinal ﬁbrovascular mem-
branes from patients with PDR and
correlated EMMPRIN levels with the
levels of the angiogenic factor VEGF
and the MMPs, MMP-1 and MMP-9.
In addition, we investigated the expres-
sion of EMMPRIN in the retinas of
diabetic rats. Finally, we evaluated the
eﬀect of EMMPRIN on the induction
of angiogenesis regulatory factors in
human retinal microvascular endothe-
lial cells (HRMECs).
Materials and Methods
Vitreous samples and epiretinal membrane
specimens
We studied undiluted vitreous ﬂuid
samples obtained from 40 patients with
PDR during pars plana vitrectomy as
described (Abu El-Asrar et al. 2015).
The severity of retinal neovascular
activity was graded at the time of
vitrectomy on the basis of previously
published criteria. Neovascularization
was considered active if there were
visible new vessels on the retina or
optic disc present within the epiretinal
membranes. Neovascularization was
considered inactive if only non-vascu-
larized, white ﬁbrotic epiretinal mem-
branes were present (Aiello et al. 1994).
Active PDR was present in 20 patients,
and inactive PDR was present in 20
patients. The total PDR group con-
sisted of a subgroup of 15 patients who
had insulin-dependent diabetes mellitus
and another subgroup of 25 patients
who had non-insulin-dependent dia-
betes mellitus. The non-diabetic subject
group consisted of 19 patients who had
undergone vitrectomy for the treatment
of rhegmatogenous retinal detachment
with no proliferative vitreoretinopathy.
Epiretinal ﬁbrovascular membranes
were obtained from 12 patients with
PDR during pars plana vitrectomy for
the repair of tractional retinal detach-
ment. Membranes were ﬁxed for 2 hr
in 10% formalin solution and embed-
ded in paraﬃn.
The study was conducted according
to the tenets of the Declaration of
Helsinki. All the patients were candi-
dates for vitrectomy as a surgical proce-
dure. All patients signed a preoperative
informed written consent and approved
the use of the excised epiretinal mem-
branes and vitreous ﬂuid for further
analysis and clinical research. The study
design and the protocol were approved
by theResearchCentre and Institutional
Review Board of the College of Medi-
cine, King Saud University.
Rat streptozotocin-induced diabetes model
All procedures with animals were per-
formed in accordance with the ARVO
statements for the use of animals in
ophthalmic and vision research and
were approved by the Institutional
Animal Care and Use Committee of
the College of Pharmacy, King Saud
University. Adult male Sprague Daw-
ley rats, 8–9 weeks of age weighting in
the range of 220–250 g, were overnight
fasted and a single high dose of strep-
tozotocin (STZ; 65 mg/kg in 10 mM
sodium citrate buﬀer, pH 4.5; Sigma,
St. Louis, MO, USA) was injected
intraperitoneally. Equal volumes of
citrate buﬀer were injected into control
animals. Measurement of blood glu-
cose concentrations and body weight
was started 3 days after injection of
STZ. Diabetes was conﬁrmed by assay-
ing the glucose concentration in blood
taken from the tail vein. Rats with
glucose levels >250 mg/dl were catego-
rized as diabetic. After 4 weeks of dia-
betes, animals were anesthetized by
intraperitoneal injection of an overdose
of chloral hydrate and killed by decapi-
tation. Retinas were dissected, ﬂash
frozen and stored at 70°C until use.
Similarly, retinas were obtained from
age-matched non-diabetic control rats.
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Cell culture
Primary HRMECs were purchased
from Cell Systems Corporation (Kirk-
land, Washington, USA) and main-
tained in complete serum-free media
(Cat. No. SF-4Z0-500, Cell System
Corporation) supplemented with re-
combinant RocketFuel (Cat No. SF-
4Z0-500, Cell System Corporation),
CultureBoost (Cat. No. 4CB-500, Cell
System Corporation) and antibiotics
(Cat. No. 4Z0-643, Cell System Corpo-
ration) at 37°C in a humidiﬁed atmo-
sphere with 5% 150 CO2 as described
(Abu El-Asrar et al. 2015). Following
starvation, HRMECs were either left
untreated or treated with 10 ng/ml of
recombinant active human (rh) EMM-
PRIN protein fragment (Cat. No.
ab155636, Abcam, Cambridge, UK)
for 24 hr and then harvested.
Enzyme-linked immunosorbent assays
Enzyme-linked immunosorbent assay
(ELISA) kits for human EMMPRIN
(Cat No: ab119592), human MMP-1
(Cat No: ab100603) and human MMP-
9 (Cat No: ab100610) were purchased
from Abcam. An ELISA kit for human
VEGF (Cat No: SVE00) was pur-
chased from R&D Systems, Min-
neapolis, MN, USA. The minimum
detection limits for the EMMPRIN,
MMP-1, MMP-9 and VEGF ELISA
kits were 2 pg/ml, 8 pg/ml, 10 pg/l and
9 pg/ml, respectively. The ELISA plate
readings were done using a Stat Fax-
4200 microplate reader from Aware-
ness Technology, Inc., Palm City, FL.
The quantiﬁcation of human EMM-
PRIN/CD147, MMP-1, MMP-9 and
VEGF in vitreous ﬂuids was deter-
mined using ELISA kits according to
the manufacturer’s instructions as des-
cribed (Abu El-Asrar et al. 2015).
Western blot analysis
Human retinal microvascular endothe-
lial cells (HRMECs) were lysed after
harvest with RIPA buﬀer [50 mM Tris–
HCl (pH 7.5), 150 mM NaCl, 1% (v/v)
Nonidet P40 (NP40), 0.5% sodium
deoxycholate, 0.1% SDS and protease
inhibitor ‘Complete without EDTA’
(Roche,Mannheim,Germany)].Whole-
cell extracts from diﬀerent treated
groups were centrifuged at 12 000 9 g
for10 minat4°C.Thesupernatantswere
collected and protein concentrations
were measured with the use of DC
proteinassaykit (Bio-RadLaboratories,
Hercules, CA, USA). Equal amounts of
protein were subjected to SDS–poly-
acrylamide gel electrophoresis (SDS–
PAGE) in 8–10% gels and transferred
onto nitrocellulose membranes (Bio-
Rad Laboratories). To determine the
expressionofEMMPRINinthevitreous
samples, equal volumes (15 ll) of vitre-
ous samples were boiled in Laemmli’s
sample buﬀer (1:1, v/v) under reducing
conditions for 10 min and analysed as
described (Abu El-Asrar et al. 2015).
Blots were then incubated at 4°C over-
night using the following primary anti-
bodies: anti-HIF-1a (1:500; sc 53546,
Santa Cruz, Biotechnology Inc., Santa
Cruz, CA, USA), anti-MMP-1 (1:1000,
MAB 901, R&D Systems), anti-VEGF
(1:500,Cat.No.MAB293R&DSystems)
and anti-EMMPRIN (1:1000, Cat. No.
ab108317, Abcam) as described (AbuEl-
Asrar et al. 2015).
Immunohistochemical staining
ForCD31anda-smoothmuscle actin (a-
SMA), antigen retrieval was performed
by boiling the sections in citrate-based
buﬀer (pH 5.9–6.1; BOND Epitope
Retrieval Solution 1; Leica, Newcastle
upon Tyne, UK) for 10 min. For CD45
and EMMPRIN detection, antigen re-
trieval was performed by boiling the
sections in Tris–EDTA buﬀer (pH 9;
BOND Epitope Retrieval Solution 2;
Leica) for 20 min. Subsequently, the
sections were incubated for 60 min with
mouse monoclonal anti-CD31 (ready to
use; clone JC70A; Dako, Glostrup,
Denmark), mouse monoclonal anti-
CD45 (ready to use; clones 2B11+PD7/
26; Dako), mouse monoclonal anti- a-
SMA (ready to use; clone 1A4; Dako)
andrabbitmonoclonal anti-EMMPRIN
antibody (1:200; ab108317, Abcam).
Optimal working concentrations and
incubation times for the antibodies were
determined earlier in pilot experiments
on glioblastoma sections as described
(Abu El-Asrar et al. 2013, 2015). Omis-
sion or substitution of the primary anti-
body with an irrelevant antibody from
the same species (rabbit monoclonal
anti-human oestrogen receptor a; ready
to use; clone EPI, Dako) and staining
with chromogen alone were used as
negative controls.
Real-time reverse transcription polymerase
chain reaction (RT-PCR)
Total RNA was extracted from retina
using TRI reagent (Ambion, TX,USA),
according to manufacturer’s protocol.
cDNAs were synthesized from 1 lg
RNA, using an high capacity cDNA
reverse transcription kit (Applied Bio-
system, Carlsbad, CA, USA ) following
the manufacturer’s instructions. Real-
time RT-PCR was performed using a
SYBR green PCRmaster mix. The PCR
primers for rat were as follows: EMM-
PRIN/CD147 forward 50-ACAGCAG
TGGCATTGACATC-30 and reverse 50-
TGTTCCGATTTCTTTCCCAC-300
and b-actin forward 50-CCTCTATGC-
CAACACAGT GC-30 and reverse 50-
CATCGTACTCCTGCTTGCTG-30.
The standard PCR conditions included
2 min at 50°C and 10 min at 95°C
followed by 40 cycles of extension at
95°C for 15 s and one min at 60°C.
Threshold lines were automatically
adjusted to intersect ampliﬁcation lines
in the linear portion of the ampliﬁca-
tion curves and cycle to threshold (Ct)
values were recorded automatically.
Data were normalized with b-actin
mRNA levels (housekeeping gene)
and the fold change in gene expression
relative to normal was calculated using
the ddCt method (Livak & Schmittgen
2001).
Zymography
Gelatinolytic levels of MMP-2 and
MMP-9 were estimated in culture
media by zymography technique. The
samples (5–20 ll) were electrophoresed
under non-reducing conditions onto
10% SDS–PAGE polymerized with
1 mg/ml gelatin. After washing the
gel with 2.5% Triton-X-100, it was
incubated overnight at 37°C in sub-
strate buﬀer containing 50 mM Tris–
HCl, pH 8.0, 5 mM CaCl2 and 0.02%
NaN. The gel was stainedwith Coomas-
sie Blue stain (0.5% Coomassie Blue
R-250, 5% methanol and 10% acetic
acid), followed by destaining (5%
methanol, 10% acetic acid). The image
was taken with the GENESYS (version
1.2.0.0) software on a G: Box machine
(Syngene, Cambridge, UK) and signal
intensityofbands (forMMP-9:~92 kDa
and for MMP-2: ~70 kDa) was quanti-
ﬁed using the Gene Tools software
(Syngene).
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Statistical analysis
Data are presented as mean values with
standard deviations indicated between
parentheses. The nonparametricMann–
Whitney U-test was used to compare
means from two independent groups.
Pearson correlation coeﬃcients were
computed to investigate correlation
between variables. A p-value <0.05
indicated statistical signiﬁcance. SPSS
version 20.0 for Windows (IBM Inc.,
Chicago, IL, USA) was used for statis-
tical analysis.
Results
ELISA levels of EMMPRIN, VEGF,
MMP-1 and MMP-9 in vitreous samples
Extracellular matrix metalloproteinase
inducer (EMMPRIN) was detected in
all vitreous samples from patients with
PDR and the non-diabetic control
patients. The mean EMMPRIN level
in vitreous samples from PDR patients
[1248.4 pg/ml; standard deviation (542.8
pg/ml)] was signiﬁcantly higher than the
mean level in non-diabetic control
patients [586.2 pg/ml (389.5 pg/ml)] (p <
0.0001; Mann–Whitney U-test; Fig. 1).
When patients with PDR were divided
into those with active neovasculariza-
tion and those with quiescent disease,
the mean level of EMMPRIN in the
vitreous samples from patients with
active PDR [1464.9 pg/ml (592.8 pg/
ml)] was signiﬁcantly higher than in the
patients with inactive PDR [1031.8 pg/
ml (393.2 pg/ml)] (p = 0.015; Mann–
Whitney U-test).
Vascular endothelial growth factor
(VEGF)wasdetected in15of19 (78.9%)
vitreous samples fromnon-diabetic con-
trol patients and in 29 of 40 (72.5%)
vitreous samples from patients with
PDR. Mean VEGF level in vitreous
samples from PDR patients [484.9 pg/
ml (893.9 pg/ml)] was signiﬁcantly
higher than the mean level in non-
diabetic control patients [39.5 pg/ml
(36.3 pg/ml)] (p = 0.001; Mann–Whit-
ney U-test; Fig. 1). The mean VEGF
level in the vitreous samples from
patients with active PDR [781.3 pg/ml
(1186.1 pg/ml)] was signiﬁcantly higher
than in the patients with inactive PDR
[188.6 pg/ml(221.0 >pg/ml)] (p = 0.03;
Mann–WhitneyU-test).MMP-1wasnot
detected in vitreous samples from non-
diabetic control patients. However,
MMP-1 was detected in 12 of 40
(30%) vitreous samples from patients
with PDR. The mean MMP-1 level in
vitreous samples from PDR patients
[25.9 pg/ml (51.7 pg/ml)] was signiﬁ-
cantly higher than the mean level in
non-diabetic control patients (p =0.009;
Mann–Whitney U-test; Fig. 1). The
mean level of MMP-1 did not diﬀer
signiﬁcantly between patients with
active PDR [42.7 pg/ml (67.2 pg/ml)]
and patients with inactive PDR [9.1 pg/
ml (19.6 pg/ml)] (p = 0.102; Mann–
Whitney U-test).
In comparison with MMP-1, about a
thousand-fold higher levels of MMP-9
were detected in PDR samples. MMP-9
was detected in all vitreous samples from
patients with PDR and non-diabetic
control patients. The meanMMP-9 level
in vitreous samples from PDR patients
[17790.3 pg/ml (10679.1 pg/ml)] was sig-
niﬁcantly higher than the mean level in
Fig. 1. Comparison of mean extracellular matrix metalloproteinase inducer (EMMPRIN), vascular endothelial growth factor (VEGF), matrix
metalloproteinase-1 (MMP-1) and MMP-9 levels in vitreous ﬂuid samples between patients with proliferative diabetic retinopathy (n = 40) and
control patients without diabetes (RD; n = 19). *The diﬀerence between the two means was statistically signiﬁcant at 5% level of signiﬁcance.
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non-diabetic control patients [7509.5 pg/
ml (5028.6 pg/ml)] (p < 0.0001; Mann–
Whitney U-test; Fig. 1). The MMP-9
levels varied widely and themean level of
MMP-9 did not diﬀer signiﬁcantly
between patients with active PDR
[20058.0 pg/ml (10545.6 pg/ml)] and
patients with inactive PDR [5522.5 pg/ml
(10585.4 pg/ml)] (p = 0.137; Mann–
Whitney U-test).
Correlations
Signiﬁcant positive correlations were
found between the vitreous ﬂuid levels
of EMMPRIN and the levels of
VEGF (r = 0.38; p = 0.003), MMP-1
(r = 0.36; p = 0.005) and MMP-9
(r = 0.46; p = 0.003). Signiﬁcant posi-
tive correlations were observed
between vitreous ﬂuid levels of MMP-
9 and levels of VEGF (r = 0.27;
p = 0.036) and MMP-1 (r = 0.38;
p = 0.003).
Western blot analysis of vitreous samples
With the use of Western blot analysis
of equal volumes (15 lL) of vitreous
samples, we conﬁrmed that EMM-
PRIN was expressed in vitreous sam-
ples from patients with PDR (n = 12)
and control patients without diabetes
(n = 12). Extracellular matrix
metalloproteinase inducer (EMM-
PRIN) protein migrated as one protein
band on SDS–PAGE when
immunoblotted and analysed with the
speciﬁc antibody at approximately
52 kDa. Densitometric analysis of the
bands demonstrated a signiﬁcant
increase in EMMPRIN in vitreous sam-
ples from PDR patients compared to
controlpatients (p = 0.005;Mann–Whit-
neyU-test; Fig. 2).
Immunohistochemical analysis of
epiretinal membranes
To identify possible sources of vitreous
ﬂuid EMMPRIN, epiretinal ﬁbrovas-
cular membranes from patients with
PDR were studied by immunohisto-
chemical analysis. No staining was
observed in the negative control studies
(Fig. 3A). All membranes showed
blood vessels that were positive for
the endothelial cell marker (CD31;
Fig. 3B). Strong immunoreactivity for
EMMPRIN was present in all mem-
branes and was noted in vascular
endothelial cells, intravascular leuco-
cytes, stromal cells and stromal spin-
dle-shaped cells (Fig. 3C,D). In serial
sections, the distribution and morphol-
ogy of stromal cells expressing EMM-
PRIN were similar to those of cells
expressing the leucocyte common
antigen CD45 (Fig. 3E). In addition, the
distribution and morphology of spindle-
shaped stromal cells expressing EMM-
PRIN (Fig. 3C) were similar to those of
spindle-shapedstromalcells expressing the
myoﬁbroblastmarker a-SMA (Fig. 3F).
EMMPRIN induces upregulation of angio-
genesis regulatory factors in HRMEC
To conﬁrm the positive correlation
between the vitreous ﬂuid levels of
EMMPRIN and the levels of VEGF,
MMP-1 and MMP-9, we performed
short-term induction experiments on
HRMEC with EMMPRIN. HRMECs
were stimulated for 24 hr with 10 ng/
ml rh EMMPRIN, and we compared
the levels of expression of HIF-1a,
VEGF and MMP-1 in the whole-cell
extracts by Western blot analysis. We
found that EMMPRIN treatment
increased the expression of HIF-1a,
VEGF and MMP-1 (Fig. 4). Gelatin
zymography analysis of the 24 hr
in vitro culture media showed that
EMMPRIN treatment did not induce
major changes in MMP-2 and MMP-9
expression levels (data not shown).
Severity of hyperglycaemia and effect of
diabetes on retinal mRNA levels of
EMMPRIN in experimental rats
After induction of diabetes with a
single dose of STZ, the body weights
of the diabetic rats were signiﬁcantly
lower and their blood glucose values
were more than fourfold higher com-
pared with age-matched normal con-
trol rats [169 g (18 g) versus 253 g
(22 g) and 467 mg/dl (28 mg/dl) versus
107 mg/dl (10 mg/dl), respectively].
Retinal mRNA levels of EMMPRIN
in the diabetic rats were increased by
about twofold as compared to non-
diabetic control rats (p = 0.02;
Mann–Whitney U-test; Fig. 5). This
result is in line with the threefold
increase of EMMPRIN protein in
human samples.
Discussion
In the present study, we showed for the
ﬁrst time that EMMPRIN was signif-
icantly upregulated in the vitreous ﬂuid
from patients with PDR and in the
retinas of diabetic rats. Our subgroup
analysis showed that the vitreous levels
of EMMPRIN were higher in PDR
eyes with active neovascularization
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Fig. 2. The expression levels of extracellular matrix metalloproteinase inducer (EMMPRIN) in
equal volumes (15 ll) of vitreous ﬂuid samples obtained from patients with proliferative diabetic
retinopathy (PDR; n = 12) and from control patients without diabetes (RD; n = 12) were
determined with Western blot analysis. A representative set of samples is shown. The resultant
data are presented in the histogram as mean  standard deviation. The expression of EMMPRIN
is signiﬁcantly increased in vitreous samples from PDR patients compared to control patients
without diabetes. *The diﬀerence between the two means was statistically signiﬁcant at 5% level of
signiﬁcance.
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compared with the eyes with quiescent
disease. In addition, we found a signif-
icant positive correlation between the
vitreous ﬂuid levels of EMMPRIN and
those of the MMPs MMP-1 and
MMP-9 and the angiogenic biomarker
VEGF, a key angiogenic factor in PDR
(Spranger & Pfeiﬀer 2001). Using
immunohistochemistry, we demon-
strated that EMMPRIN was localized
in vascular endothelial cells, leucocytes
expressing the leucocyte common anti-
gen CD45 and myoﬁbroblasts in
epiretinal ﬁbrovascular membranes
from patients with PDR.
Cancer cells overexpressing EMM-
PRIN stimulate upregulation of VEGF
(Tang et al. 2005, 2006) and the MMPs
MMP-1, MMP-2 and MMP-9 (Tang
et al. 2004, 2005, 2006; Millimaggi
et al. 2007). Interestingly, EMMPRIN
also induced its own gene expression
(Tang et al. 2004). Increased expression
of membrane-associated EMMPRIN in
tumour cells was accompanied by an
MMP-dependent generation of a sol-
uble form of EMMPRIN, representing
a proteolytic cleavage product lacking
the carboxyl terminus. Soluble EMM-
PRIN is functional in stimulating
MMP expression in ﬁbroblast and
endothelial cells (Tang et al. 2004).
These ﬁndings suggest that increased
expression of MMPs in the ocular
microenvironment of patients with
PDR may result in proteolytic cleavage
of membrane-associated EMMPRIN,
releasing soluble EMMPRIN. Soluble
EMMPRIN in turn acts in a paracrine
fashion to further stimulate the pro-
duction of VEGF, MMPs and addi-
tional EMMPRIN, which consequently
contributes to PDR angiogenesis and
progression.
(A) (B)
(C) (D)
(E) (F)
Fig. 3. Proliferative diabetic retinopathy (PDR) epiretinal ﬁbrovascular membrane immunos-
tainings. A negative control slide that was treated identically with an irrelevant antibody showing
no labelling (A). Immunohistochemical staining for CD31 showing blood vessels positive for
CD31 (B). Immunohistochemical staining for extracellular matrix metalloproteinase inducer
(EMMPRIN) showing immunoreactivity in the vascular endothelium (arrows) in intravascular
leucocytes, in stromal cells and in stromal spindle-shaped cells (arrowheads) in a membrane from a
patient with active PDR (C) and in a membrane from a patient with inactive PDR (D).
Immunohistochemical staining for CD45 showing stromal cells positive for CD45 (E). Immuno-
histochemical staining for a-smooth muscle actin showing immunoreactivity in spindle-shaped
myoﬁbroblasts (F) (original magniﬁcation 409).
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Fig. 4. Human retinal microvascular endothe-
lial cells were left untreated (Control) or
treated with 10 ng/ml of extracellular matrix
metalloproteinase inducer (EMMPRIN) for
24 hr. Protein expressions of hypoxia-induci-
ble factor-1a (HIF-1a) (A), vascular endothe-
lial growth factor (B) and matrix
metalloproteinase-1 (MMP-1) (C) were deter-
mined by Western blot analysis. Western blots
are representative of at least two independent
experiments (n ≥ 11) and bar graphs are rep-
resentative of all experiments. *p < 0.05 com-
pared to untreated control.
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In the present study, we detected
simultaneous expression of EMM-
PRIN, VEGF, MMP-1 and MMP-9
in the vitreous ﬂuid from patients with
PDR. There were signiﬁcant positive
correlations between the levels of
EMMPRIN and the levels of VEGF,
MMP-1 and MMP-9. These ﬁndings
are in accordance with previous reports
that demonstrated active involvement
of EMMPRIN in the upregulation of
VEGF (Tang et al. 2005; Bougatef
et al. 2009), MMP-1 (Tang et al.
2004; Millimaggi et al. 2007) and
MMP-9 (Tang et al. 2004, 2005,
2006). In the current study, EMM-
PRIN was localized in vascular
endothelial cells and stromal cells in
PDR epiretinal ﬁbrovascular mem-
branes. Similarly, in previous studies,
we demonstrated VEGF (Abu El-Asrar
et al. 2007) and MMP-9 (Abu El-Asrar
et al. 2013) localization in vascular
endothelial cells and stromal cells in
epiretinal membranes from patients
with PDR. The coexpression of these
angiogenesis regulatory factors in the
ocular microenvironment of patients
with PDR suggests a crosstalk between
these factors in the pathogenesis of
PDR angiogenesis and progression and
that the coexpression of these factors is
mechanistically interrelated.
Angiogenesis involves the activation
and invasion of endothelial cells
through their basement membrane,
migration to distal sites and tube for-
mation. It has been demonstrated that
EMMPRIN contributes to each of
these events and promotes the angio-
genic phenotype in human endothelial
cells in vitro (Millimaggi et al. 2007;
Bougatef et al. 2009; Chen et al. 2009).
In addition, EMMPRIN has a potent
anti-apoptotic eﬀect on endothelial
cells (Chen et al. 2009). Several vascu-
lar regulatory proteins and growth
factors have been shown to be acti-
vated or upregulated by EMMPRIN in
endothelial cells. Extracellular matrix
metalloproteinase inducer selectively
upregulated the expression of VEGF,
VEGFR-2, HIF-1a and HIF-2a in
humandermalmicrovascularendothelial
cells(Bougatefet al.2009).Itwasdemon-
strated that EMMPRIN-induced endo-
thelial cell migration and tube formation
is mediated by VEGF/VEGFR-2 sig-
nalling (Bougatef et al. 2009). Further-
more, EMMPRIN inducedupregulation
of MMP-1, MMP-2, and MMP-9 in
human umbilical vein endothelial cells
(Millimaggiet al.2007;Chenet al.2009).
Recently, it was demonstrated that
EMMPRIN enhanced VEGF-induced
VEGFR-2 phosphorylation in human
dermal microvascular endothelial cells,
downstream signalling of the VEGF-
induced pathway and consequently cell
migration (Khayati et al. 2015). In the
current study, we conﬁrmed that stimu-
lation with EMMPRIN caused small
upregulation of HIF-1a, VEGF and
MMP-1inHRMEC.Additionally,EMM
PRIN was demonstrated to recruit bone
marrow-derived cells,which contribute to
tumour neovascularization (Chen et al.
2015). In previous studies, we demon-
strated that bone marrow-derived endo-
thelial precursor cells contribute to
neovascularizationinPDR(AbuEl-Asrar
et al. 2010, 2011).
Recent data show that in addition to
its well-characterized role in cancer,
EMMPRIN activity may represent an
important determinant in the pathogen-
esis of organ ﬁbrosis (Kato et al. 2011;
Yan et al. 2015; Hasaneen et al. 2016).
Fibroblasts overexpressing EMMPRIN
had a signiﬁcant increase in cell prolif-
eration and migration and showed a
signiﬁcantly increased expression of a-
SMA, a marker of diﬀerentiation to
myoﬁbroblasts. Furthermore, EMM-
PRIN promoted ﬁbroblasts resistance
to apoptosis (Hasaneen et al. 2016).
Extracellular matrix metalloproteinase
inducer and a-SMA were colocalized to
the same cells in epiretinal ﬁbrovascular
membranes from patients with PDR,
thus supporting a role for EMMPRIN
in the diﬀerentiation of myoﬁbroblasts
in vivo.
In conclusion, we suggest that the
EMMPRIN/MMPs/VEGF pathway is
involved in PDR angiogenesis and
progression. Consequently, the devel-
opment of eﬀective therapeutic inter-
ventions to inhibit EMMPRIN (Gwinn
et al. 2006; Agrawal et al. 2012) would
provide a novel and potentially power-
ful alternative to current treatments.
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